Gaucher Disease Treatment Market Offers Lucrative Growth Opportunities Driven by Rising R&D Investments

Gaucher Disease Treatment Market Offers Lucrative Growth Opportunities Driven by Rising R&D Investments

Market Overview:
Gaucher disease is a rare autosomal recessive genetic disorder caused by a mutation in the Glucosylceramidase (GBA) gene. This leads to a deficiency in β-glucocerebrosidase enzyme which breaks down glycosphingolipid glucocerebroside. The disorder is characterized by accumulation of glucocerebroside in macrophages which affects spleen, liver and bone marrow. The signs and symptoms include bruising easily, fatiguability, anemia, enlarged spleen or liver, low platelet count, bone and joint pains. The disease occurs in three main forms- type 1 is non-neurological, type 2 is acute neurological and type 3 manifests sub-acute neurological symptoms. Treatment includes enzyme replacement therapies, substrate reduction therapy, bone marrow transplant, symptomatic therapies and nutritional supplements. Leading drugs in the market include Cerezyme, Vpriv, Elelyso and Cerdelga.

Market Dynamics:
The global Gaucher Disease Treatment Market Share is witnessing lucrative growth opportunities driven by increasing R&D investments from major players. For instance, in June 2023, Shire announced positive results from phase III Tactic study evaluating investigational eliglustat tartrate for the long-term treatment of type 1 Gaucher disease. The study met its primary endpoint, demonstrating non-inferiority of eliglustat compared with imiglucerase. Moreover, rising prevalence of Gaucher disease worldwide is augmenting market growth. According to National Gaucher Foundation, Gaucher

Segment Analysis
The global Gaucher disease treatment market is segmented into type and end user. Based on type, the market is segmented into type 1 Gaucher disease, type 2 Gaucher disease, and type 3 Gaucher disease. Among them, the type 1 Gaucher disease segment dominated the market in 2021 due to high prevalence of this type of the disease. Based on end user, the market is divided into hospitals, clinics, and others. The hospitals segment captured the largest market share in 2021 as these are the primary points of contact for patients experiencing symptoms.

PEST Analysis
Political: The growth of the market is supported by increasing initiatives by governments and non-profit organizations to raise awareness about lysosomal storage disorders like Gaucher disease.
Economic: Rising per capita healthcare expenditure in developing nations provides numerous growth opportunities in the market.
Social: Growing patient assistance programs by key players cater to the needs of families affected by rare diseases and boost the uptake of Gaucher disease treatments.
Technological: Advancements in fields of gene therapy, nanotechnology, and medical imaging assist in early diagnosis and development of new treatment methods for Gaucher disease.

Key Takeaways
The global Gaucher disease treatment market is expected to witness high growth, exhibiting a CAGR of 2.50% over the forecast period, due to increasing research towards treatments for rare genetic disorders. Regionally, North America dominated the market and held the largest revenue share in 2021 owing to presence of major players and growing diagnosis rates in the region. The key players operating in the Gaucher disease treatment market are Genzyme Corporation, Pfizer, Inc., Shire Human Genetics Therapies, Inc., and Actelion Pharmaceuticals Ltd. (acquired by Johnson & Johnson in June 2017). There are various drugs in pipeline of companies such as Lixte Biotechnology Holdings Inc, JCR Pharmaceuticals Co Ltd, Pharming Group NV and Orphazyme ApS, for Gaucher disease treatment.

Read More:

https://www.pressreleasebulletin.com/gaucher-disease-treatment-market-poised-for-growth/